Novartis’ Newly Acquired Atrsentan P-III (ALIGN) Study Shows Positive Interim Results in IgA Nephropathy
Shots:
- Novartis plans to submit these 36wks. interim results for accelerated approval from FDA, where Atrasentan showed a reduction in proteinuria vs PBO in IgA Nephropathy patients
- The P-III (ALIGN) study is planned to continue for up to 136wks. in order to assess eGFR with confirmatory results expected by Q1’26
- Novartis recently acquired Chinook for Atresentan & Zigabikart (SC) both of which are under P-III clinical evaluation in IgAN patients. Additionally, the company recently published results for its organic Iptacopan (Factor B inhibitor) in IgAN patients
Ref: Novartis| Image: Novartis
Related News:- Novartis’ Cosentyx (secukinumab) Receives the US FDA’s Approval as First Intravenous Formulation for Rheumatic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
